Short peptide therapy agent for inhibiting activity of cancer cells and medicine composition comprising same

A technology of pharmaceutical composition and therapeutic agent, which is applied in the field of short peptide therapeutic agent and the pharmaceutical composition containing it, and can solve the problems such as poor cancer treatment effect

Active Publication Date: 2016-12-07
王育民
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Although there are some small-molecule anticancer drugs currently on the market, such as cis-diammine dichloroplatinum (II); CDDP; trade name Cisplatin), paclitaxel (trade name Taxol) and 5-Fluorouracil (5-Fluorouracil; 5-FU), etc. However, recent studies have found that the above-mentioned small molecule anticancer drugs not only activate the expression of CEBPD in cancer cells, but also activate the expression of CEBPD in macrophages and fibroblasts, Instead, it promotes drug resistance and rapid metastasis of cancer cells, resulting in ineffective cancer treatment
[0008] In view of this, there is an urgent need to develop a small molecule anticancer drug to overcome the problems of known small molecule anticancer drugs such as drug resistance and rapid metastasis of tumor cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Short peptide therapy agent for inhibiting activity of cancer cells and medicine composition comprising same
  • Short peptide therapy agent for inhibiting activity of cancer cells and medicine composition comprising same
  • Short peptide therapy agent for inhibiting activity of cancer cells and medicine composition comprising same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Embodiment 1: Preparation of short peptide therapeutic agent

[0054] In this embodiment, artificially synthesized short peptide RI37 (with the amino acid sequence shown in SEQ ID NO: 1), short peptide GI40 (with the amino acid sequence shown in SEQ ID NO: 2) and short peptide KT44 (with The amino acid sequence shown in SEQ ID NO:3) was used as a short peptide therapeutic agent, and the polypeptide pPTX3 / C (with the amino acid sequence shown in SEQ ID NO:4) was used as a control group. The sequence design of the short peptide RI37, short peptide GI40, short peptide KT44, and polypeptide euPTX3 is as follows: Figure 1A Shown, and the sequence design of short peptide RI37, short peptide GI40, polypeptide pPTX3 / C and polypeptide euPTX3 is as follows Figure 5A shown.

[0055] The above-mentioned short peptide RI37, short peptide GI40 and short peptide KT44 can be synthesized by entrusting Coronet International Technology Co., Ltd. (Taipei, Taiwan), for example. The abov...

Embodiment 2

[0056] Example 2: Establishing a cell test model

[0057] This embodiment utilizes human breast cancer cell line (MDA-MB231, which is preserved in Taiwan Hsinchu Food Industry Development Institute (FIRDI, No. 331 Food Road, Hsinchu City, Taiwan 300) Biological Resource Preservation and Research Center (BCRC), deposit number: BCRC 60425, this cell line is also preserved in the American Type Culture Collection (ATCC, P.O. Box1549, Manassas, VA 20108, USA), deposit number: ATCC HTB-26; hereinafter referred to as MB231) or the cisplatin-resistant breast cancer cell line (CDDP-resistant MDA-MB231, MDA-MB231R; hereinafter referred to as MBR), human lung cancer cell line A549 (preservation number: BCRC 60074; ATCC CCL-185), human nasopharyngeal carcinoma cell line HONE1 (Int.J.Cancer.1990Jan 15; 45 (1): 83-9; Proc.Natl.Acad.Sci.USA, Vol.86, pp.9524-9528, December 1989) etc., evaluate the effect of the short peptide therapeutic agent of embodiment one on cancer cell activity Inhibit...

Embodiment 3

[0059] Example Three: Inhibition of Cancer Cell Activity by Short Peptide Therapeutic Agents

[0060] After the short peptide therapeutic agent of Example 1 was added to the cells of Example 2 for co-cultivation, relevant evaluation was carried out in the following manner.

[0061] 1. Assessing the Effect of Short Peptides on Cancer Cell Proliferation

[0062] After the short peptide RI37, short peptide GI40 and short peptide KT44 of Example 1 were co-cultured with the breast cancer cell MB231 of Example 2 for 24 hours or 48 hours, MTT[3-(4,5-dimethylthiazol-2-yl) -2,5-diphenol tetrazolium bomide] (Sigma), for cytotoxicity test. MTT is tetrazolium salt (tetrazolium salt). After being decomposed by mitochondrial dehydrogenase in living cells, blue formazan (formazan) crystals are produced from transparent and colorless. The cell survival rate without adding the short peptide of Example 1 is taken as 100 %, thus judging the effect of the short peptide in Example 1 on the proli...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a short peptide therapy agent and a medicine composition comprising same. The short peptide therapy agent comprises at least one short peptide represented by the amino acid sequences SEQ ID No.1 and SEQ ID No.2; any one of the short peptides includes not more than forty amino acid residues. The therapy agent can inhibit activities, such as proliferation, cancer stemness, migration, invasion, metastasis or drug resistance, etc., of the cancer cells.

Description

technical field [0001] The invention relates to a peptide and its application, in particular to a short peptide therapeutic agent for inhibiting the activity of cancer cells and a pharmaceutical composition containing it to inhibit the activity of cancer cells. Background technique [0002] For cancer patients with metastatic or inoperable malignant tumors, after surgical resection of the primary site of the tumor, further chemotherapy will be given to inhibit the proliferation and metastasis of potential cancer cells. However, even for cancer patients who claim chemotherapy success, the possibility of cancer recurrence or even drug-resistant cancer cannot be ruled out. Patients with relapsed cancer, especially those with drug resistance during chemotherapy, are often at increased risk because the relapsed cancer cells metastasize more rapidly. [0003] Taking cancer as an example, it is known that cancer cells can stimulate the microenvironment around the tumor to produce ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/00A61K38/16A61P35/00A61P35/04
Inventor 王育民萧郁韦纪智瑛
Owner 王育民
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap